Compare Weibo Corp (WB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Weibo Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Weibo Corp trades at $6.67 (market cap $1.65B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Weibo Corp pays a 9.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Weibo Corp nearer its low. Which is the better fit depends on your goals.
| WB | XBI | |
|---|---|---|
Market Cap | $1.65B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $12.83 | $169.55 |
52-Week Low | $6.63 | $93.43 |
Enterprise Value | $878.79M | — |
Dividend Yield | 9.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Weibo (WB) trades at $6.70, down 0.3% on the day, with a bearish technical signal despite low valuation ratios like a P/E of 5.53 and P/B of 0.41. Recent Q2 2026 earnings beat expectations with EPS of $0.38, but revenue growth remains stagnant at $1.76 billion in 2025. Cash flow trends show volatility, with a net outflow of $694 million in 2024, though 2025 improved to a $408 million inflow.
The stock presents a deep-value opportunity with strong profitability margins, but faces headwinds from declining user engagement and intense competition. Analyst sentiment is mixed with a near-even split between buy and hold ratings, reflecting uncertainty over long-term growth catalysts amid a bearish technical outlook.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
